New study shows ubrogepant may enhance migraine relief
It would provide pain relief and will no disrupt daily life
(Web Desk) - A recent study published in Neurology, the medical journal of the American Academy of Neurology, suggests that ubrogepant, a CGRP inhibitor, could significantly improve migraine treatment.
The research indicates that taking ubrogepant at the onset of migraine symptoms may help individuals maintain their daily activities with minimal disruption.
The study, which involved 518 participants experiencing migraines 2 to 8 times per month, tested the efficacy of ubrogepant in treating early migraine signs.
Participants were divided into two groups: one group took a placebo initially and ubrogepant during a second migraine attack, while the other group received ubrogepant first and a placebo later.
They were asked to rate their activity limitations on a scale from 0 (not limited) to 4 (extremely limited) in a daily diary.
The findings revealed that 65% of those who took ubrogepant felt "not at all limited" or "a little limited" 24 hours later, compared to 48% of those who took the placebo.
Two hours after taking the medication, ubrogepant users were 73% more likely to report no disability than those who received the placebo.
These results suggest that early administration of ubrogepant could be effective in managing migraines, allowing sufferers to continue their daily routines with less interruption.
However, the study noted a potential limitation: the reliance on self-reported diary entries, which could introduce inaccuracies.
